• Explore /
  • Poster
  • / A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

A randomized phase 2 study of durvalumab monotherapy and in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS study.

Abstract Poster

Authors

Eileen M. O'Reilly

Eileen Mary O'Reilly

Memorial Sloan Kettering Cancer Center, New York, NY

Eileen Mary O'Reilly , Do-Youn Oh , Neesha Dhani , Daniel John Renouf , Myung Ah Lee , Weijing Sun , George A. Fisher Jr., Aram F. Hezel , Shao-Chun Chang , Gordana Vlahovic , Osamu Takahashi , Yin Yang , Philip Agop Philip

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Prevention, Diagnosis, and Screening

Clinical Trial Registration Number

NCT02558894

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 217)

DOI

10.1200/JCO.2018.36.4_suppl.217

Abstract #

217

Poster Bd #

A14

Abstract Disclosures

Similar Posters

First Author: Daniel John Renouf

First Author: Ho Yeong Lim

First Author: Viktor Grünwald

First Author: Ronan Joseph Kelly